Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 183,442 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: NOT program Clear all
Terminated No phase listed Observational

A-SPIRE Heart Failure: Utilizing Health Tags to Identify Patients at Risk for Hospital Readmissions

NCT04550052
View directory record Official record
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 2, 2026, 11:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Respiratory Rate Validation Study - Mindset Medical Informed Vital Core Application

NCT06508047
View directory record Official record
Conditions
Vital Sign Evaluation
Interventions
Informed Vital Core App
Device
Lead sponsor
Mindset Medical
Industry
Eligibility
22 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Louisville, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 2, 2026, 11:59 AM EDT
Terminated Phase 1 Interventional

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma

NCT05065047
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 2, 2026, 11:59 AM EDT
Available No phase listed Expanded access

Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

NCT06956547
View directory record Official record
Conditions
Lymphopenia
Interventions
nogapendekin-alfa inbakicept
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Bioanalytical Assays for Tebipenem

NCT05856747
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TBP-PI-HBr
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Creve Coeur, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Sep 2, 2026, 11:59 AM EDT
Recruiting No phase listed Observational

QOL and Sarcopenia in Patients With Ascites

NCT05726747
View directory record Official record
Conditions
Ascites Hepatic, Ascites, Malignant
Interventions
Quality of Life surveys
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Not applicable Interventional Results available

Pilot Study of an Intimacy Enhancement Intervention for Couples Facing Breast Cancer

NCT02721147
View directory record Official record
Conditions
Breast Cancer
Interventions
Intimacy Enhancing Intervention, Living Healthy Together, Partner-Assisted Coping Skills Training, Behavioral, Psychological or Informational Intervention
Behavioral
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 2, 2026, 11:59 AM EDT
Withdrawn Phase 1 Interventional

Pharmacokinetics and Safety of MNK-155 in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain

NCT02767349
View directory record Official record
Conditions
Acute Pain
Interventions
MNK-155
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
12 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Influence of a Monopoly Game on Subtle Behaviors

NCT02470949
View directory record Official record
Conditions
Obesity, Eating Behavior
Interventions
Low Social Status, High Social Status
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
19 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Sep 2, 2026, 11:59 AM EDT
Active, not recruiting Phase 2 Interventional

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

NCT01746849
View directory record Official record
Conditions
Leukemia, Multiple Myeloma, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma
Interventions
Palifermin, Lupron, peripheral blood stem cell transplantation, Total-Body Irradiation (TBI), Thiotepa, Cyclophosphamide, Degarelix
Biological · Procedure · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 2, 2026, 11:59 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

NCT03743649
View directory record Official record
Conditions
Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Haloperidol, Lorazepam, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Phase 3 Interventional Results available

Use of N-Acetylcysteine (NAC) in Fingernail Biting

NCT01993849
View directory record Official record
Conditions
Onychophagia
Interventions
N-Acetylcysteine (NAC), Placebo
Drug · Other
Lead sponsor
Kevin Gray, MD
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 2, 2026, 11:59 AM EDT
Terminated Not applicable Interventional

Assessing Neurocognitive Effects of Gluten Exposure

NCT01506349
View directory record Official record
Conditions
Celiac Disease, Neurobehavioral Manifestations
Interventions
gluten, Placebo
Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 2, 2026, 11:59 AM EDT
Completed No phase listed Observational

Correlating Time-Lapse Parameters Detected by the Eeva™ System With Comprehensive Chromosome Screening Results

NCT01635049
View directory record Official record
Conditions
Infertility
Interventions
Not listed
Lead sponsor
Progyny, Inc.
Industry
Eligibility
Up to 43 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Morristown, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Phase 4 Interventional Results available

Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder

NCT00190749
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

ACTIVE: Advanced Cognitive Training for Independent and Vital Elderly

NCT00298558
View directory record Official record
Conditions
Aging, Healthy
Interventions
Cognitive Training
Behavioral
Lead sponsor
Carelon Research
Other
Eligibility
65 Years and older
Enrollment
2,832 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Phase 3 Interventional

Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome

NCT00190658
View directory record Official record
Conditions
Failure to Thrive
Interventions
Somatropin (rDNA origin) for injection
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
3 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2010 · Synced Sep 2, 2026, 11:59 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

NCT04108858
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma
Interventions
Copanlisib, Pertuzumab, Trastuzumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

NCT01280058
View directory record Official record
Conditions
Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Wild-type Reovirus
Drug · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Supplements and Personal Energy Tracking Device to Promote and Maintain Healthy Weight

NCT00502658
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Dietary supplement containing vitamins, minerals, and herbs, Shakes with nutrients and herbs, Control dietary supplement, Isocaloric, isonitrogenous control shakes without herbs, Personal energy tracking tool
Behavioral
Lead sponsor
Pharmanex
Industry
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Provo, Utah
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Phase 2 Interventional

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

NCT00181558
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate
Interventions
Atrasentan, Zoledronic Acid (Zometa)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 9, 2010 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Phase 1 Interventional

BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)

NCT04018248
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, B Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Peripheral T Cell Lymphoma
Interventions
BR101801 (Phase Ia), BR101801 (Phase Ib)
Drug
Lead sponsor
Boryung Pharmaceutical Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Not applicable Interventional

The Utility of Virtual Reality in the Management of Pediatric Functional Constipation With Pelvic Floor Dysfunction.

NCT04172948
View directory record Official record
Conditions
Functional Constipation, Pelvic Floor Disorders
Interventions
Oculus go headset/virtual reality headset, Diaphragmatic breathing
Device · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 2, 2026, 11:59 AM EDT
Completed Phase 1Phase 2 Interventional

A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study

NCT02875548
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epitheliod Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL)
Interventions
Tazemetostat
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
11
States / cities
Tucson, Arizona • Santa Fe, California • Port Saint Lucie, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 2, 2026, 11:59 AM EDT